A phase 1 study to evaluate the dose, safety and tolerability of a radionuclide therapy (Radspherin®) in patients with platinum sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma with peritoneal carcinomatosis following complete surgical resection
Phase 1
Not yet recruiting
- Conditions
- Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis
- Registration Number
- 2024-511851-16-00
- Lead Sponsor
- Oncoinvent ASA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruitment pending
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
UZ Leuven
🇧🇪Leuven, Belgium
Clinica Universidad De Navarra
🇪🇸Pamplona, Spain
Oslo University Hospital HF
🇳🇴Oslo, Norway
UZ Leuven🇧🇪Leuven, BelgiumEls Van NieuwenhuysenSite contact+3116345126Els.vannieuwenhuysen@uzleuven.be